U.S. markets closed
  • S&P 500

    -84.79 (-1.89%)
  • Dow 30

    -450.02 (-1.30%)
  • Nasdaq

    -385.10 (-2.72%)
  • Russell 2000

    -36.12 (-1.78%)
  • Crude Oil

    -0.61 (-0.70%)
  • Gold

    -6.50 (-0.35%)
  • Silver

    -0.37 (-1.50%)

    +0.0031 (+0.27%)
  • 10-Yr Bond

    -0.0860 (-4.69%)

    -0.0045 (-0.33%)

    -0.4500 (-0.39%)

    -2,858.91 (-7.51%)
  • CMC Crypto 200

    +628.18 (+258.85%)
  • FTSE 100

    -90.88 (-1.20%)
  • Nikkei 225

    -250.67 (-0.90%)

908 Devices to Exhibit at ASMS and Present Key Developments in Accelerating Proteomics Workflows

  • Oops!
    Something went wrong.
    Please try again later.
·4 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • MASS

BOSTON, October 27, 2021--(BUSINESS WIRE)--At the American Society of Mass Spectrometry (ASMS) conference October 31 to November 4 in Philadelphia, 908 Devices Inc. (Nasdaq: MASS) is presenting several talks and posters on the use of high-pressure mass spectrometry and microfluidics separation technologies to accelerate drug discovery workflows, including in metabolomics and proteomics applications. The company, a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, is also launching a new ZipChip assay kit that enables fast and accurate identification and quantitation of oligonucleotides.

A Revolution in Chemical and Biochemical Analysis

Proteomics and metabolomics continue to increase in importance in the development of new therapeutics. "Widely available genetic sequencing tools unlocked genomic knowledge and discovery, and it is widely acknowledged that the proteomics and metabolomics revolutions are next," said Dr. Christopher D. Brown, CTO and co-founder, 908 Devices. "Research in these areas have already dramatically expanded the visibility we have into both the state and trajectory of extremely complex biological systems."

Bolstered by the remarkable success of rapid COVID-19 vaccine development, scientists are looking for more tools to accelerate discovery and development workflows. At ASMS, Drs. Scott Mellors and Will Thompson, research scientists at 908 Devices, will present recent microfluidic prototype chip developments and associated analysis algorithm approaches for the company’s ZipChip ecosystem in the proteomics and metabolomics application spaces. Jarrod Marto and He Zhu, leading researchers at Dana-Farber Cancer Institute in Boston, are utilizing the prototypes to perform proteomics assays of deubiquitinating enzymes. At ASMS, they will present their ‘warp-speed profiling’ in comparison to a traditional liquid chromatography-based workflow.

ZipChip integrates with Thermo Fisher, Sciex, and Bruker mass spectrometers and leverages microfluidic-based Capillary Electrophoresis (CE) and electrospray ionization technology to minimize sample prep burden, perform high-resolution separations and directly introduce samples into a mass spec.

Other presentations at ASMS include a talk and poster on the new ZipChip Oligos assay kit, which provides a fast and simple means to obtain high-resolution separation and mass spec data from a wide range of oligonucleotides. Two posters will also be presented on quantitation of metabolites in cell culture media using Rebel, a desktop CE-MS analyzer, which enables biopharma researchers to accelerate process development cycles and maximize their bioreactor utilization.

Exhibit and Presentations at ASMS

908 Devices will exhibit its handheld and desktop devices in booth #306 at ASMS, and here is a list of ASMS presentations by 908 Devices and select customers:

November 1

  • Decreasing Analysis Time, Sample Requirements, and Avoiding MS Incompatible Solvents by Employing ZipChip CZE-MS Technology for Oligonucleotide Analysis (Adi Kulkarni, 908 Devices on behalf of Jennifer Lippens, Amgen)

  • Microchip CE-MS with Integrated Solid Phase Extraction (Scott Mellors, 908 Devices)

November 2

  • Warp-speed Selectivity Profiling of Small Molecule Inhibitors Using µSPE Chip-based CE-MS with PRM-LIVE Acquisition on an Ion Mobility Mass Spectrometer (He Zhu/Jarrod Marto, Dana-Farber Cancer Institute and Harvard Medical School)

  • Increasing Intact mAb Charge Variant Separation Resolution with Microfluidic CE-MS (Erin Redman, 908 Devices)

November 3

  • Indexed Migration Time (iMT) for Improved Peak Identification in High Throughput Metabolomics by Capillary Electrophoresis-Mass Spectrometry (Will Thompson, 908 Devices)

November 4

  • High-throughput Product Quality Assessment of Protein Therapeutics on ZipChip-MS platform (Wen Chen, Ligand Pharmaceuticals)

  • Microchip CE-MS of Oligonucleotides: What Can it Separate? (Adi Kulkarni, 908 Devices)

  • Quantitation of Metabolites in Classical and Customized Cell Culture Medias by an Integrated CE-MS Analyzer (Kenion Blakeman, 908 Devices)

  • Quantitation of Metabolites in Cell Culture Media by an Integrated CE-MS Analyzer for Upstream Process Development (Ji Young Anderson, 908 Devices)

To learn more about 908 Devices, please visit: 908devices.com.

About 908 Devices

908 Devices is democratizing laboratory mass spectrometry with its simple handheld and desktop devices, addressing critical-to-life applications. The Company’s devices are used at the point-of-need to interrogate unknown and invisible materials and provide quick, actionable answers to directly address some of the most critical problems in life sciences research, bioprocessing, pharma / biopharma, forensics and adjacent markets. The Company is headquartered in the heart of Boston, where it designs and manufactures innovative products that bring together the power of mass spectrometry, microfluidic separations, software automation, and machine learning.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211027005157/en/


Media Contact
Katie Johnston
PAN Communications for 908 Devices

Investor Contact
Carrie Mendivil